z-logo
open-access-imgOpen Access
Mechanisms involved in the antinociceptive effect caused by diphenyl diselenide in the formalin test
Author(s) -
Savegnago Lucielli,
Jesse Cristiano R.,
Santos Adair R. S.,
Rocha João B. T.,
Nogueira Cristina W.
Publication year - 2008
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1211/jpp.60.12.0015
Subject(s) - chemistry , diphenyl diselenide , nociception , pharmacology , apamin , charybdotoxin , nitric oxide , diselenide , biochemistry , medicine , receptor , selenium , calcium , organic chemistry
This study investigated the mechanisms involved in the antinociceptive action induced by diphenyl diselenide ((PhSe) 2 ) in the formalin test. Mice were pre‐treated with (PhSe) 2 by the oral route (0.1–100 mg kg −1 ), 30 min before formalin injection. To address some of the mechanisms by which (PhSe) 2 inhibits formalin‐induced nociception mice were treated with different drugs. The antinociceptive effect of (PhSe) 2 was shown in the first and second phases of the formalin test. The antinociceptive effect caused by (PhSe) 2 (10 mg kg −1 , p.o.) was prevented by intrathecal injection of K + channel blockers such as apamin and charybdotoxin (small‐ and large‐conductance Ca 2+ ‐activated K + channel inhibitors, respectively) and tetraethylammonium (TEA, a non‐selective voltage‐dependent K + channel inhibitor), but not glib‐enclamide (an ATP‐sensitive K + channel inhibitor). The antinociceptive action caused by (PhSe) 2 (10 mg kg −1 , p.o.) was also blocked by a nitric oxide (NO) synthase inhibitor (N ω ‐nitro‐ l ‐arginine, L‐NOARG) and the soluble guanylate cyclase inhibitors 1 H ‐[1,2,4]oxadiazolo[4,3‐ a ]quinoxalin‐1‐one (ODQ) and methylene blue. These results suggest the participation of NO/cyclic GMP/Ca 2+ and K + channel pathways in the antinociceptive effect caused by (PhSe) 2 .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here